IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma

Seiji Kishi, Masanori Minato, Atsuro Saijo, Naoka Murakami, Masanori Tamaki, Motokazu Matsuura, Taichi Murakami, Kojiro Nagai, Hideharu Abe, Yasuhiko Nishioka, Toshio Doi

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient’s renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury.

Original languageEnglish
Pages (from-to)1259-1263
Number of pages5
JournalInternal Medicine
Volume57
Issue number9
DOIs
StatePublished - 2018

Keywords

  • Glomerular injury
  • IgA nephropathy
  • Immune-related adverse events (irAEs)
  • Nivolumab
  • Onconephrology

Fingerprint

Dive into the research topics of 'IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this